Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor over-expression, and inhibition of the IL-6/JAK/STAT pathway by treatment with ruxolitinib or tocilizumab restores CD38 levels.”
Authors: Wataru Kuroki, Akihiro Kitadate, Yuto Takahashi, Sayaka Iwama, Masahiro Yamada, Takahiro Kobayashi, Sho Ikeda, Kentaro Narita, Kosei Matsue, Naoto Takahashi.
More posts featuring Robert Orlowski.
